Obios is redefining obesity treatment with our data-driven prescription system based on the Drinkometer, a medical device, and our software. Targeting the $100B anti-obesity medication market, we enhance prescription precision, moving away from the current trial and error approach.
Our Drinkometer tracks ingestive behaviour, the only biomarker directly associated with anti-obesity medications outcome. Our software leverages these insights allowing tailored treatment.
This research-based approach enables doctors to make informed prescriptions, improving patient outcomes, cutting healthcare costs and streamlining drug production.
With 50 ready-to-buy opinion leaders and strategic pharmaceutical partnerships, Obios is advancing to set a new benchmark in anti-obesity medication prescription.